-
1 Comment
Double Medical Technology Inc is currently in a long term downtrend where the price is trading 5.4% below its 200 day moving average.
From a valuation standpoint, the stock is 45.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 14.0.
Double Medical Technology Inc's total revenue rose by 33.8% to $437M since the same quarter in the previous year.
Its net income has increased by 20.9% to $163M since the same quarter in the previous year.
Finally, its free cash flow grew by 32.0% to $83M since the same quarter in the previous year.
Based on the above factors, Double Medical Technology Inc gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | SHE |
CurrencyCode | CNY |
ISIN | CNE1000032W7 |
Market Cap | 22B |
---|---|
PE Ratio | 47.64 |
Target Price | 43.82 |
Dividend Yield | 0.8% |
Beta | 0.1 |
Double Medical Technology Inc. engages in the research, development, production, sale, and service of medical products in China. The company provides products for orthopedics, minimally invasive surgery, neurosurgery, maxillofacial, chest wall, hernia, wound repair surgery, and dentistry, as well as minimally invasive spinal endoscopy and regenerative medicine. It also exports its products to various countries and regions. The company was formerly known as Xiamen Da Bo Ying Jing Medical Equipment Company Limited. Double Medical Technology Inc. was incorporated in 2004 and is based in Xiamen, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002901.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025